Aerodynamically light particles for pulmonary drug delivery

Abstract

Improved aerodynamically light particles for drug delivery to the pulmonary system, and methods for their synthesis and administration are provided. In a preferred embodiment, the aerodynamically light particles are made of biodegradable material and have a tap density of less than 0.4 g / cm3 and a mass mean diameter between 5 μm and 30 μm. The particles may be formed of biodegradable materials such as biodegradable polymers. For example, the particles may be formed of a functionalized polyester graft copolymer consisting of a linear α-hydroxy-acid polyester backbone having at least one amino acid group incorporated therein and at least one poly(amino acid) side chain extending from an amino acid group in the polyester backbone. In one embodiment, aerodynamically light particles having a large mean diameter, for example greater than 5 μm, can be used for enhanced delivery of a therapeutic agent to the alveolar region of the lung. The aerodynamically light particles incorporating a therapeutic agent may be effectively aerosolized for administration to the respiratory tract to permit systemic or local delivery of wide variety of therapeutic agents.

Description

RELATED APPLICATIONS[0001]This application is a continuation of U.S. patent application Ser. No. 10 / 027,212, filed Dec. 20, 2001 now U.S. Pat. No. 6,635,283 which is a continuation of U.S. patent application Ser. No. 09 / 562,988, filed May 1, 2000 now U.S. Pat. No. 6,399,102, which is a continuation of U.S. patent application Ser. No. 09 / 211,940, filed Dec. 15, 1998, now U.S. Pat. No. 6,136,295, which is a Divisional of U.S. application Ser. No. 08 / 739,308 filed on Oct. 29, 1996, now U.S. Pat. No. 5,874,064 which is a continuation-in-part of U.S. patent application Ser. No. 08 / 655,570, filed on May 24, 1996 now abandoned. The entire teachings of the above applications are incorporated herein by reference.BACKGROUND OF THE INVENTION[0002]The present invention relates generally to biodegradable particles of low density and large size for drug delivery to the pulmonary system.[0003]Biodegradable particles have been developed for the controlled-release and delivery of protein and peptide...

AI Technical Summary

Benefits of technology

[0011]Improved aerodynamically light particles for drug delivery to the pulmonary system, and methods for their synthesis and administration are provided. In a preferred embodiment, the particles are made of a biodegradable material, have a tap density less than 0.4 g / cm3 and a mean diameter between 5 μm and 30 μm. In one embodiment, for example, at least 90% of the particles have a mean diameter between 5 μm and 30 μm. The particles may be formed of biodegradable materials such as biodegradable polymers, proteins, or other water-soluble materials. For example, the particles may be formed of a functionalized polyester graft copolymer consisting of a linear α-hydroxy-acid polyester backbone having at least one amino acid residue incorporated per molecule therein and at least one poly(amino acid) side chain extending from an amino acid group in the polyester backbone. Other examples include particles formed of water-soluble excipients, such as trehalose or lactose, or proteins, such as lysozyme or insulin. The aerodynamically light particles can be used for enhanced delivery of a therapeutic agent to the airways or the alveolar region of the lung. The particles incorporating a therapeutic agent may be effectively aerosolized for administration to the respiratory tract to permit systemic or local delivery of a wide variety of therapeutic agents. They optionally may be co-delivered with larger carrier particles, not carrying a therapeutic agent, which have for example a mean diameter ranging between about 50 μm and 100 μm.

Problems solved by technology

However, pulmonary drug delivery strategies present many difficulties for the delivery of macromolecules; these include protein denaturation during aerosolization, excessive loss of inhaled drug in the oropharyngeal cavity (often exceeding 80%), poor control over the site of deposition, irreproducibility of therapeutic results owing to variations in breathing patterns, the often too-rapid absorption of drug potentially resulting in local toxic effects, and phagocytosis by lung macrophages.

Attention has not been given to the possibility of using large particle size (>5 μm) as a means to improve aerosolization efficiency, despite the fact that intraparticle adhesion diminishes with increasing particle size.

This is because particles of standard mass density (mass density near 1 g / cm3) and mean diameters >5 μm are known to deposit excessively in the upper airways or the inhaler device.

Slow release from a therapeutic aerosol can prolong the residence of an administered drug in the airways or acini, and diminish the rate of drug appearance in the bloodstream.

However, increasing the particle size also minimizes the probability of particles (possessing standard mass density) entering the airways and acini due to excessive deposition in the oropharyngeal or nasal regions.

Images